Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
Baumgartner C, Gleixner KV, Peter B, Ferenc V, Gruze A, Remsing Rix LL, Bennett KL, Samorapoompichit P, Lee FY, Pickl WF, Esterbauer H, Sillaber C, Superti-Furga G, Valent P. Baumgartner C, et al. Among authors: peter b. Exp Hematol. 2008 Oct;36(10):1244-53. doi: 10.1016/j.exphem.2008.04.017. Epub 2008 Jul 10. Exp Hematol. 2008. PMID: 18619723 Free article.
Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.
Hadzijusufovic E, Rebuzzi L, Gleixner KV, Ferenc V, Peter B, Kondo R, Gruze A, Kneidinger M, Krauth MT, Mayerhofer M, Samorapoompichit P, Greish K, Iyer AK, Pickl WF, Maeda H, Willmann M, Valent P. Hadzijusufovic E, et al. Among authors: peter b. Exp Hematol. 2008 Nov;36(11):1461-70. doi: 10.1016/j.exphem.2008.06.002. Epub 2008 Aug 23. Exp Hematol. 2008. PMID: 18723263 Free article.
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Hadzijusufovic E, Peter B, Rebuzzi L, Baumgartner C, Gleixner KV, Gruze A, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Willmann M, Valent P. Hadzijusufovic E, et al. Among authors: peter b. Vet Immunol Immunopathol. 2009 Dec 15;132(2-4):243-50. doi: 10.1016/j.vetimm.2009.05.007. Epub 2009 May 18. Vet Immunol Immunopathol. 2009. PMID: 19505729 Free PMC article.
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V, Kneidinger M, Baumgartner C, Mayerhofer M, Gruze A, Pickl WF, Sillaber C, Valent P. Aichberger KJ, et al. Among authors: peter b. Blood. 2009 Dec 17;114(26):5342-51. doi: 10.1182/blood-2008-08-175190. Epub 2009 Oct 22. Blood. 2009. PMID: 19850739 Free article.
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.
Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Müllauer L, Willmann M, Valent P. Peter B, et al. Haematologica. 2011 May;96(5):672-80. doi: 10.3324/haematol.2010.031328. Epub 2011 Jan 17. Haematologica. 2011. PMID: 21242189 Free PMC article.
The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
Herrmann H, Kneidinger M, Cerny-Reiterer S, Rülicke T, Willmann M, Gleixner KV, Blatt K, Hörmann G, Peter B, Samorapoompichit P, Pickl W, Bharate GY, Mayerhofer M, Sperr WR, Maeda H, Valent P. Herrmann H, et al. Among authors: peter b. Curr Cancer Drug Targets. 2012 Jan;12(1):51-63. doi: 10.2174/156800912798888992. Curr Cancer Drug Targets. 2012. PMID: 22165967
359 results